CA2873890C - Methods and compositions for treating amyloid deposits - Google Patents
Methods and compositions for treating amyloid deposits Download PDFInfo
- Publication number
- CA2873890C CA2873890C CA2873890A CA2873890A CA2873890C CA 2873890 C CA2873890 C CA 2873890C CA 2873890 A CA2873890 A CA 2873890A CA 2873890 A CA2873890 A CA 2873890A CA 2873890 C CA2873890 C CA 2873890C
- Authority
- CA
- Canada
- Prior art keywords
- apoe
- protective
- mammal
- protein
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648801P | 2012-05-18 | 2012-05-18 | |
| US61/648,801 | 2012-05-18 | ||
| PCT/US2013/031725 WO2013172964A1 (en) | 2012-05-18 | 2013-03-14 | Methods and compositions for treating amyloid deposits |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2873890A1 CA2873890A1 (en) | 2013-11-21 |
| CA2873890C true CA2873890C (en) | 2022-12-06 |
Family
ID=49584137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2873890A Active CA2873890C (en) | 2012-05-18 | 2013-03-14 | Methods and compositions for treating amyloid deposits |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150183850A1 (enExample) |
| EP (1) | EP2850195B1 (enExample) |
| JP (2) | JP6469000B2 (enExample) |
| CN (2) | CN104540952A (enExample) |
| AU (1) | AU2013263346B2 (enExample) |
| BR (1) | BR112014028666B1 (enExample) |
| CA (1) | CA2873890C (enExample) |
| ES (1) | ES2786078T3 (enExample) |
| HK (1) | HK1207109A1 (enExample) |
| IN (1) | IN2014KN02672A (enExample) |
| RU (1) | RU2673484C2 (enExample) |
| WO (1) | WO2013172964A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230145206A (ko) | 2014-11-14 | 2023-10-17 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| WO2016196507A1 (en) | 2015-05-29 | 2016-12-08 | University Of Iowa Research Foundation | Methods of delivery of transgenes for treating brain diseases |
| EP3307391A1 (en) * | 2015-06-12 | 2018-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of alzheimer's disease |
| KR20180134373A (ko) * | 2016-04-14 | 2018-12-18 | 타오 헬스 라이프 파마 가부시키가이샤 | 아밀로스페로이드(aspd)형 구조체 및 의약 조성물 |
| US10584337B2 (en) | 2016-05-18 | 2020-03-10 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| CN109715194B (zh) * | 2016-08-03 | 2024-06-11 | 南佛罗里达大学 | 用于治疗神经障碍的颤蛋白组合物 |
| WO2018045347A1 (en) * | 2016-09-02 | 2018-03-08 | Spark Therapeutics, Inc. | Methods and vectors for treating cns disorders |
| EP3309550A1 (en) * | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Method for the detection of apolipoprotein e4 |
| EP3692158A4 (en) | 2017-10-03 | 2021-08-04 | Prevail Therapeutics, Inc. | GENE THERAPIES FOR LYSOSOMAL DISEASES |
| MX2020004005A (es) | 2017-10-03 | 2020-10-05 | Prevail Therapeutics Inc | Terapias genicas para los trastornos lisosomales. |
| CA3121211A1 (en) * | 2018-11-28 | 2020-06-04 | Prevail Therapeutics, Inc. | Gene therapies for neurodegenerative disease |
| JP2023500793A (ja) * | 2019-10-16 | 2023-01-11 | コーネル・ユニバーシティー | アルツハイマー病に対する遺伝子治療方法 |
| KR20220107243A (ko) | 2019-11-25 | 2022-08-02 | 코넬 유니버시티 | Apoe 유전자 요법 |
| EP4130014A4 (en) * | 2020-03-31 | 2024-05-15 | Nuo-Beta Pharmaceutical Technology (Shanghai) Co., Ltd. | Deuterated oxophenylarsine compound and use thereof |
| KR20230112672A (ko) * | 2020-11-25 | 2023-07-27 | 프리베일 테라퓨틱스, 인크. | 신경변성 질환을 위한 유전자 요법 |
| CN120187407A (zh) * | 2021-12-15 | 2025-06-20 | 健达九州(北京)生物科技有限公司 | 重组aav载体及其用途 |
| CN116063405B (zh) * | 2022-09-27 | 2025-08-29 | 广州译码基因科技有限公司 | 可提高AAV病毒包装能力的衣壳蛋白突变体MutC及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5589154A (en) * | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
| US6436996B1 (en) * | 1997-09-30 | 2002-08-20 | Duke University | Modulation of nitric oxide production |
| US6468524B1 (en) | 2000-03-22 | 2002-10-22 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | AAV4 vector and uses thereof |
| US6855314B1 (en) | 2000-03-22 | 2005-02-15 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 vector for transducing brain cells and lung cells |
| GB0322645D0 (en) * | 2003-09-26 | 2003-10-29 | Melacure Therapeutics Ab | Use of antisecretory factor peptides |
| EP1828390B1 (en) * | 2004-12-15 | 2012-06-13 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
| AU2006242129A1 (en) * | 2005-05-02 | 2006-11-09 | Genzyme Corporation | Gene therapy for spinal cord disorders |
| JP2010504909A (ja) * | 2006-09-14 | 2010-02-18 | メドジェニクス・メディカル・イスラエル・リミテッド | 長期持続性の医薬製剤 |
| CN104383556B (zh) * | 2007-05-16 | 2018-06-05 | 布里格姆妇女医院 | 突触核蛋白病的治疗 |
| CA2833912C (en) * | 2010-04-23 | 2021-09-21 | University Of Massachusetts | Aav-based treatment of cholesterol-related disorders |
-
2013
- 2013-03-14 US US14/402,064 patent/US20150183850A1/en not_active Abandoned
- 2013-03-14 ES ES13790429T patent/ES2786078T3/es active Active
- 2013-03-14 CN CN201380038140.1A patent/CN104540952A/zh active Pending
- 2013-03-14 WO PCT/US2013/031725 patent/WO2013172964A1/en not_active Ceased
- 2013-03-14 AU AU2013263346A patent/AU2013263346B2/en active Active
- 2013-03-14 HK HK15107526.1A patent/HK1207109A1/xx unknown
- 2013-03-14 BR BR112014028666-3A patent/BR112014028666B1/pt active IP Right Grant
- 2013-03-14 CA CA2873890A patent/CA2873890C/en active Active
- 2013-03-14 RU RU2014151218A patent/RU2673484C2/ru active
- 2013-03-14 EP EP13790429.8A patent/EP2850195B1/en active Active
- 2013-03-14 IN IN2672KON2014 patent/IN2014KN02672A/en unknown
- 2013-03-14 CN CN202011133829.0A patent/CN112574964A/zh active Pending
- 2013-03-14 JP JP2015512644A patent/JP6469000B2/ja active Active
-
2018
- 2018-11-02 JP JP2018207331A patent/JP2019031564A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013172964A1 (en) | 2013-11-21 |
| US20150183850A1 (en) | 2015-07-02 |
| JP2015520161A (ja) | 2015-07-16 |
| RU2673484C2 (ru) | 2018-11-27 |
| EP2850195B1 (en) | 2020-01-22 |
| IN2014KN02672A (enExample) | 2015-05-08 |
| HK1207109A1 (en) | 2016-01-22 |
| ES2786078T3 (es) | 2020-10-08 |
| CN104540952A (zh) | 2015-04-22 |
| BR112014028666B1 (pt) | 2021-12-07 |
| CA2873890A1 (en) | 2013-11-21 |
| AU2013263346A1 (en) | 2014-12-04 |
| JP2019031564A (ja) | 2019-02-28 |
| AU2013263346B2 (en) | 2018-08-23 |
| EP2850195A4 (en) | 2015-12-09 |
| BR112014028666A2 (pt) | 2017-06-27 |
| JP6469000B2 (ja) | 2019-02-13 |
| CN112574964A (zh) | 2021-03-30 |
| RU2014151218A (ru) | 2016-07-10 |
| EP2850195A1 (en) | 2015-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2850195B1 (en) | Methods and compositions for treating amyloid deposits | |
| AU2017318717B2 (en) | Methods and vectors for treating CNS disorders | |
| EP3071240B1 (en) | Method for monitoring efficacy of treatment of alzheimer's disease with an apoe isoform | |
| WO2022155435A1 (en) | Treating diseases and improving nucleic acid delivery | |
| EP4410988A1 (en) | An aav2-vector variant for targeted transfer of genes | |
| US20240115736A1 (en) | Methods and materials for treating tdp-43 proteinopathies | |
| HK1229258A1 (en) | Method for monitoring efficacy of treatment of alzheimer's disease with an apoe isoform | |
| HK1229258B (en) | Method for monitoring efficacy of treatment of alzheimer's disease with an apoe isoform | |
| BR112016011258B1 (pt) | Métodos e composiçôes para o tratamento de depósitos de amiloide | |
| KR20260004228A (ko) | Aav2-anks1a 재조합 바이러스를 포함하는 알츠하이머 질병 치료용 조성물 | |
| KR20250112089A (ko) | 퇴행성 뇌 질환의 예방 또는 치료를 위한 뇌혈관 특이적 유전자 치료용 조성물 | |
| WO2025016362A1 (zh) | 基于脑内磷稳态促进剂的疗法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180308 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250307 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250307 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250307 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260427 |